AccScience Publishing / ARNM / Online First / DOI: 10.36922/arnm.3462
CASE REPORT

Chemotherapy for a malignant peripheral nerve sheath tumor: A case report

Phuong Cam Pham1,2,3 Hien Quang Le1,3 Duong Binh Nguyen3 Hoang The Tran3 Khoa Trong Mai1,2 Thai Van Pham1,3*
Show Less
1 The Nuclear Medicine and Oncology Center, Bach Mai Hospital, Hanoi, Vietnam
2 Department of Oncology and Nuclear Medicine, University of Medicine and Pharmacy National University, Hanoi, Vietnam
3 Department of Nuclear Medicine, Hanoi Medical University, Hanoi, Vietnam
Submitted: 21 April 2024 | Accepted: 28 October 2024 | Published: 10 December 2024
© 2024 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Abstract

Malignant peripheral nerve sheath tumors (MPNSTs) are uncommon and aggressive soft-tissue sarcomas. They are difficult to manage due to their aggressiveness and limitations in early diagnosis and management. Complete surgical resection with or without adjuvant radiotherapy is the most effective treatment for patients with primary disease, whereas in those with metastatic disease, cytotoxic chemotherapy is beneficial. We herein present the case of a woman who complained of severe lower back pain. Computed tomography and magnetic resonance imaging revealed multiple bone and lung lesions. The patient underwent a bone lesion biopsy and was diagnosed with an advanced MPNST, which was appropriately treated with systemic chemotherapy.

Keywords
Malignant peripheral nerve sheath tumor
Treatment
Chemotherapy
Metastasis
Anthracycline
Enhancement
Rare cancer
Rare disease
Funding
None.
Conflict of interest
Phuong Cam Pham is an Editorial Board Member of this journal but was not in any way involved in the editorial and peer-review process conducted for this paper, directly or indirectly. Separately, other authors declared that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.
References
  1. Cai Z, Tang X, Liang H, Yang R, Yan T, Guo W. Prognosis and risk factors for malignant peripheral nerve sheath tumor: A systematic review and meta-analysis. World J Surg Oncol. 2020;18:257. doi: 10.1186/s12957-020-02036-x

 

  1. Sobczuk P, Teterycz P, Czarnecka AM, et al. Systemic treatment for advanced and metastatic malignant peripheral nerve sheath tumors-a sarcoma reference center experience. J Clin Med. 2020;9(10):3157. doi: 10.3390/jcm9103157

 

  1. Knight SWE, Knight TE, Santiago T, Murphy AJ, Abdelhafeez AH. Malignant peripheral nerve sheath tumors-a comprehensive review of pathophysiology, diagnosis, and multidisciplinary management. Children (Basel). 2022;9(1):38. doi: 10.3390/children9010038

 

  1. Farid M, Demicco EG, Garcia R, et al. Malignant peripheral nerve sheath tumors. Oncologist. 2014;19(2):193-201. doi: 10.1634/theoncologist.2013-0328

 

  1. Mehren M von, Kane JM, Agulnik M, et al. Soft tissue sarcoma, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(7):815-833. doi: 10.6004/jnccn.2022.0035

 

  1. Gronchi A, Miah AB, Dei Tos AP, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up☆. Ann Oncol. 2021;32(11):1348-1365. doi: 10.1016/j.annonc.2021.07.006

 

  1. Kroep JR, Ouali M, Gelderblom H, et al. First-line chemotherapy for Malignant Peripheral Nerve Sheath Tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: An EORTC Soft Tissue and Bone Sarcoma Group study. Ann Oncol. 2011;22(1):207-214. doi: 10.1093/annonc/mdq338
Share
Back to top
Advances in Radiotherapy & Nuclear Medicine, Electronic ISSN: 2972-4392 Published by AccScience Publishing